Aragen Life Science, formerly GVK Biosciences, secures a $100 million investment from healthcare-focused private equity fund Quadria Capital. The investment will support Aragen’s strategic expansion and infrastructure development to meet growing demand for outsourcing services from US and Europe innovators. This move positions Aragen strongly in the pharmaceutical outsourcing market, enhancing its capabilities and accelerating program delivery.
Related Posts
Family settlement: Kirloskar companies to challenge Sebi
Four Kirloskar companies plan to legally challenge Sebi’s directive to disclose a family settlement deed from 2009. They assert the deed does not impact them, […]
RBI report shows India’s forex reserves cover stands at 11.2 months of imports with a slight decline
India’s foreign exchange reserves can now cover 11.2 months of imports, down from 11.3 in March 2024, according to the RBI. Short-term debt has risen […]